Quantcast

Latest Hepatitis C virus Stories

2014-06-19 16:23:51

The Majority of Surveyed Primary Care Physicians Expect to Refer HCV Patients to a Specialist for Care, According to Findings from Decision Resources Group BURLINGTON, Mass., June 19, 2014 /PRNewswire/ -- Decision Resources Group finds that less than one-third of surveyed primary care physicians (PCPs) are familiar with the first-generation hepatitis C virus (HCV) protease inhibitors, Vertex's Incivek and Merck's Victrelis, despite the fact that these direct acting antivirals have been...

2014-06-18 12:29:54

Arrival of IFN-Free Therapies Will Bring Patients For Whom Current Therapies are Ineffective Back to the Drug-Treated Population, According to Findings from Decision Resources Group BURLINGTON, Mass., June 18, 2014 /PRNewswire/ -- Decision Resources Group finds that China's market for hepatitis C virus (HCV) drugs will be driven by an increase in its drug-treated population, following the introduction of novel HCV therapies. Nearly a third of patients diagnosed with HCV do not receive the...

2014-06-17 04:21:28

NORTH CHICAGO, Ill., June 17, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the Marketing Authorization Applications (MAAs) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection have been validated and are under accelerated assessment by the European Medicines Agency (EMA). Accelerated assessment, which is designated to new medicines of major public health...

2014-06-13 16:23:26

NORTH CHICAGO, Ill., June 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review. The NDA was submitted on April 21, 2014 and is supported by data from a large clinical program...

2014-05-29 08:29:27

SYDNEY, May 29, 2014 /PRNewswire/ -- RNAi-based therapeutics company, Benitec Biopharma Limited (ASX: BLT) is pleased to announce that it has dosed the first patient in its 'first in man', Phase I/IIa clinical trial for TT-034, a ddRNAi-based therapeutic, designed to treat and potentially cure hepatitis C (HCV) with a single injection. Benitec Biopharma's CEO and Managing Director, Peter French said, "The commencement of this clinical trial of TT-034 represents a landmark in the Company's...

2014-05-22 08:29:21

-- Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date(1) -- Health Canada grants AbbVie's request for Priority Review MONTREAL, May 22, 2014 /CNW/ - AbbVie (NYSE: ABBV) filed a New Drug Submission (NDS) to Health Canada seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including...

2014-05-19 10:12:50

University at Buffalo More effective, new medications for HCV infection with fewer side effects also are causing a shift in patients’ attitudes People who inject drugs and are enrolled in a drug treatment program are receptive to education about, and treatment for, hepatitis C virus, according to a study by researchers at several institutions, including the University at Buffalo. That finding, published online this week in the Journal of Addiction Medicine will be welcome news to...

2014-05-08 04:21:41

- Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date1 NORTH CHICAGO, Ill., May 8, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) submitted marketing authorization applications (MAAs) to the European Medicines Agency (EMA) seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. The MAAs are supported by...

2014-05-02 12:26:36

New research finds Vietnam vets with hepatitis C do not have higher rates of the disease DANVILLE, Pa., May 2, 2014 /PRNewswire-USNewswire/ -- A team of researchers from four health systems across the United States has published a study revealing that Vietnam era vets with hepatitis C virus (HCV) do not have higher rates of this disease due to injection drug abuse compared to nonveterans. The study was published electronically in the Journal of Community Health in April. It is...

2014-04-22 08:34:00

-Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date(1) NORTH CHICAGO, Ill., April 22, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. The NDA is supported by...


Latest Hepatitis C virus Reference Libraries

11_c18ff18c314281da28f1d18fa4357602
2011-01-20 19:28:48

Hepatitis E virus is an infective organism. The viral particles are 27 to 34 nanometers in diameter. They are non-enveloped and contain a single-strand of positive-sense RNA which is approximately 7300 bases in length. The virus was first visualized in 1983 and molecularly cloned in 1990. Previously it was classified in the family Caliciviridae. Its genome more closely resembles the rubella virus and is now classified as the only member of the genus Hepevirus which has not yet been...

11_9e88d15808b8ecc3fcbbdfcf4ae75786
2011-01-20 19:23:30

Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. It consists of a core of genetic material surrounded by an icosahedra protective shell of protein. The genome consists of a single open reading frame that is 9600 nucleotide bases long. HCV replication takes several steps. It primarily replicates in the hepatocytes of the liver. It can also reproduce in peripheral blood mononuclear cells. There is a wide variety of genotypes and...

More Articles (2 articles) »
Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.